Robert Ritch is an Ophthalmology physician affiliated with New York Eye and Ear Infirmary. OpenAlex indexes 35 publications with 1,299 citations (h-index 17); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
310 E 14th St
New York, NY 100034201
Telephone
212-477-7540Registry record last updated 8 Jul 2007.
Clinical trials
- Nailfold Capillary Blood Flow With Latanoprost Bunod
Sponsor: Icahn School of Medicine at Mount Sinai
- Measurement of the Effect of Gingko Biloba Extract on Ocular and Nailfold Blood-flow in NTG
Sponsor: Robert Ritch, MD, LLC.
- Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy
Sponsor: The New York Eye & Ear Infirmary
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Johnson & Johnson Surgical Vision, Inc.Program year20251 payment
- RxSight IncProgram year20231 payment
- RxSight IncProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
100%Carbonic Anhydrase Inhibitor100%Dorzolamide-Timolol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1985–2003 per NIH RePORTER. The latest:
- COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
New York Eye and Ear Infirmary
FY2003$14,593U10EY009142 - COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
New York Eye and Ear Infirmary
FY2002$74,314U10EY009142 - COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
New York Eye and Ear Infirmary
FY2001$72,534U10EY009142
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The XFG- Associated Deaminase LOXL1 Is An Intrinsically Disordered Protein With A High Aggregative Ability.
Investigative Ophthalmology & Visual Science
2019 - Tank-Binding Kinase 1 (<i>TBK1</i>) Gene and Open-Angle Glaucomas (An American Ophthalmological Society Thesis).
PubMed
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Mark Kupersmith, MD
New York Eye and Ear Infirmary
Janet Serle, MD
New York Eye and Ear Infirmary
Ronald Gentile, MD
New York Eye and Ear Infirmary
Paul Sidoti, MD
New York Eye and Ear Infirmary
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”